FR

Maxime J Fleury

This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maxime J Fleury. Retrieved from https://idiyas.com/inventor/maxime-j-fleury

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Maxime J Fleury: Innovator in HPV Therapeutics

Introduction

Maxime J Fleury is a notable inventor based in France, recognized for his contributions to the field of therapeutic innovations. His work primarily focuses on modified HPV particles, which have significant implications for treating various diseases.

Latest Patents

Maxime J Fleury holds a patent titled "HPV Particles and Uses Thereof." This invention relates to modified HPV particles that can be utilized therapeutically. These modified HPV particles are designed to deliver therapeutic agents, including siRNA molecules. They may be employed in the treatment of diseases or conditions affecting mucosal tissue, particularly HPV (human papilloma virus) infections and HPV-related tumors. Despite his innovative work, he currently has 0 patents.

Career Highlights

Throughout his career, Maxime has worked with esteemed organizations such as the National Institute of Health and Medical Research and Aura Biosciences, Inc. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Maxime has collaborated with notable colleagues, including Pierre L Coursaget and Antoine A Touze. These partnerships have enriched his research endeavors and fostered innovation in the field of HPV therapeutics.

Conclusion

Maxime J Fleury's work in developing modified HPV particles showcases his commitment to advancing therapeutic options for HPV-related conditions. His contributions to the field are significant and reflect his dedication to innovation in medical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…